Receptor Binding
Introduction
Section titled “Introduction”Receptor binding is the fundamental process by which peptides exert their biological effects. Understanding receptor types, binding kinetics, and dose-response relationships is essential for drug design and therapeutic development.
Major Receptor Types
Section titled “Major Receptor Types”G-Protein Coupled Receptors (GPCRs)
Section titled “G-Protein Coupled Receptors (GPCRs)”GPCRs are the largest family of membrane receptors and the most common target for peptide drugs. They share a characteristic structure with seven transmembrane domains (seven alpha-helices spanning the membrane), an extracellular N-terminus for ligand binding, an intracellular C-terminus for G-protein coupling, and three intracellular and three extracellular loops.
Signaling mechanism: peptide binds to extracellular domain, conformational change in receptor, activation of intracellular G-protein, dissociation of Gα and Gβγ subunits, activation of effector enzymes, and second messenger production.
Examples include opioid receptors (endorphins), oxytocin receptor, vasopressin receptors, and substance P receptor (NK1).
Ion Channel Receptors
Section titled “Ion Channel Receptors”Ion channel receptors are ligand-gated ion channels that allow rapid signal transmission. They consist of multiple subunits forming a central pore with a ligand binding site on the extracellular domain, a selectivity filter in the pore region, and a gate mechanism for channel opening. Examples include the nicotinic acetylcholine receptor (cation channel), GABA-A receptor (chloride channel), NMDA receptor (calcium channel), and P2X receptors (ATP-gated cation channels).
Enzyme-Linked Receptors
Section titled “Enzyme-Linked Receptors”Enzyme-linked receptors have intrinsic enzymatic activity or associate with intracellular enzymes. Major types include receptor tyrosine kinases (RTKs) that phosphorylate tyrosine residues, receptor serine/threonine kinases, and receptor-associated kinases. Examples include the insulin receptor, IGF-1 receptor, and TGF-β receptors. Signaling involves peptide binding inducing dimerization, autophosphorylation, adaptor protein recruitment, and downstream signaling cascades.
Ligand-Receptor Binding Kinetics
Section titled “Ligand-Receptor Binding Kinetics”Affinity describes the strength of interaction between a ligand and receptor, measured by the dissociation constant (Kd = [L][R] / [LR]). Lower Kd means higher affinity. Typical Kd values range from nanomolar (10⁻⁹ M) to picomolar (10⁻¹² M).
Selectivity describes a ligand’s preference for one receptor subtype over others. The binding process involves both association (k_on) and dissociation (k_off) rates, where Kd = k_off / k_on.
Agonists, Antagonists, and Partial Agonists
Section titled “Agonists, Antagonists, and Partial Agonists”| Type | Affinity | Efficacy | Response |
|---|---|---|---|
| Full Agonist | High | High | Maximal |
| Partial Agonist | Moderate | Moderate | Submaximal |
| Antagonist | Variable | None | Blocks agonist |
| Inverse Agonist | Variable | Negative | Opposite to agonist |
Dose-Response Relationships
Section titled “Dose-Response Relationships”The dose-response curve relates drug concentration to biological effect. Key parameters include EC₅₀ (concentration producing 50% of maximal effect, a measure of potency) and Emax (maximum achievable effect, a measure of efficacy).
The Hill equation describes this relationship: E = Emax × [C]ⁿ / (EC₅₀ⁿ + [C]ⁿ), where n is the Hill coefficient measuring cooperativity.
The therapeutic window is the range of drug concentrations that produces therapeutic effect without unacceptable toxicity. The therapeutic index (TD₅₀ / ED₅₀) indicates safety margin.